Non-clinical development
Strong clinical development starts with evidence that answers the right questions. Clarenta helps you define and coordinate the non-clinical activities needed to understand your candidate, prepare for regulatory review and support a well-founded transition into clinical development.
Our specialists connect scientific strategy, CMC development and regulatory requirements, helping you identify gaps, anticipate risks and focus resources where they will have the greatest impact.
Early phase development
Early phase studies shape the direction of everything that follows. Clarenta brings clinical pharmacology, medical, regulatory and operational expertise together to help you move from first clinical evaluation to evidence that supports confident decisions.
We support studies in healthy volunteers, patients and specialist populations, including First-in-Human, proof-of-concept, PK and clinical pharmacology, and early phase oncology trials. Strategy stays connected to execution, emerging data and the next decisions your team needs to make.
Therapeutic insight behind every decision
Development decisions become stronger when they reflect the realities of the disease, the patient population and the treatment pathway. Clarenta brings therapeutic understanding into scientific strategy and early clinical development, helping your team anticipate challenges and interpret evidence in the right context.
Our experience spans oncology and onco-haematology, rare diseases, neurology and psychiatry, respiratory diseases, dermatology, gastroenterology and other complex therapeutic areas.